Published in Proc Natl Acad Sci U S A on December 01, 1981
The hypersensitive glucocorticoid response specifically regulates period 1 and expression of circadian genes. Mol Cell Biol (2012) 1.06
Cortisol rapidly reduces prolactin release and cAMP and 45Ca2+ accumulation in the cichlid fish pituitary in vitro. Proc Natl Acad Sci U S A (1991) 0.83
Immunoassay of endogenous plasma insulin in man. J Clin Invest (1960) 25.67
Radioimmunoassay for cyclic nucleotides. I. Preparation of antibodies and iodinated cyclic nucleotides. J Biol Chem (1972) 8.24
Specific binding sites for oestrogen at the outer surfaces of isolated endometrial cells. Nature (1977) 3.04
Membrane effects of thyrotropin-releasing hormone and estrogen shown by intracellular recording from pituitary cells. Science (1979) 1.33
Substances modulating the secretion of ACTH by cultured anterior pituitary cells. Fed Proc (1977) 1.13
Differences in corticosterone and dexamethasone binding to rat brain and pituitary. Endocrinology (1975) 1.11
Enrichment of cell types from the rat adenohypophysis by sedimentation at unit gravity. Endocrinology (1973) 1.04
Structure-activity relationships for inhibitors of phosphodiesterase from erythrocytes and other tissues. Adv Cyclic Nucleotide Res (1972) 0.93
Effects of acute stress on serum LH and prolactin in intact, castrate and dexamethasone-treated male rats. Endocrinology (1975) 0.93
Prolactin release by vasoactive intestinal polypeptide in rats. Endocrinology (1978) 0.92
Specific interaction of corticosteroids with binding sites in the plasma membranes of the rat anterior pituitary gland. J Endocrinol (1978) 0.91
Vasoactive intestinal peptide: evidence for a hypothalamic site of action to release growth hormone, luteinizing hormone, and prolactin in conscious ovariectomized rats. Endocrinology (1979) 0.91
The relationship between glucocorticoid structure and effects upon thymocytes. Mol Pharmacol (1977) 0.90
Vasoactive intestinal peptide (VIP) stimulates prolactin (PRL) release and cAMP production in a rat pituitary cell line (GH3/B6). Additive effects of VIP and TRH on PRL release. FEBS Lett (1979) 0.90
Modification of stress-induced prolactin release by dexamethasone or adrenalectomy. Endocrinology (1975) 0.89
The role of glucocorticoid hormones as biological amplifiers. Monogr Endocrinol (1979) 0.89
Stimulation of prolactin release by vasoactive intestinal peptide (VIP). Eur J Pharmacol (1978) 0.88
Evidence for a specific mineralocorticoid receptor in rat pituitary and brain. J Steroid Biochem (1980) 0.87
Estradiol-induced increase of the LH responsive to LH releasing hormone (LHRH) in rat anterior pituitary cells in culture. Endocrinology (1976) 0.87
Steroid hormone receptors and pharmacology. J Steroid Biochem (1980) 0.87
Heterogeneity of pituitary glucocorticoid binding evidence for a transcortin-like compound. Biochim Biophys Acta (1976) 0.86
A putative glucocorticoid receptor and a transcortin-like macromolecule in pituitary cytosol. Biochim Biophys Acta (1976) 0.86
Specific binding sites for natural glucocorticoids in plasma membranes of rat liver. Endocrinology (1975) 0.86
VIP activation of rat anterior pituitary adenylate cyclase. FEBS Lett (1979) 0.86
Stimulation of in vitro prolactin release by vasoactive intestinal peptide. Neuroendocrinology (1980) 0.84
Effects of glucocorticoids on pituitary hormonal responses to hypoglycemia. Inhibition of prolactin release. J Clin Endocrinol Metab (1975) 0.84
Effect of dexamethasone on prolactin and TSH responses to TRH and metoclopramide in man. J Clin Endocrinol Metab (1977) 0.82
Vasoactive intestinal polypeptide: release into hypophyseal portal blood. Life Sci (1979) 0.81
Relationship between ACTH release and corticosterone binding by the receptor sites of the adenohypophysis and dorsal hippocampus following infusion of corticosterone at a constant rate in the adrenalectomized rat. Endocrinology (1975) 0.81
Effect of vasoactive intestinal peptide (VIP) on the release of adenohypophyseal hormones from purified cells obtained by unit gravity sedimentation. Inhibition by dexamethasone of vip-induced prolactin release. Neuroendocrinology (1980) 0.81
Glucocorticoid suppression of pancreatic and pituitary hormones: pancreatic polypeptide, growth hormone, and prolactin. J Clin Endocrinol Metab (1980) 0.80
Effect of vasoactive intestinal polypeptide on prolactin release in vitro. Life Sci (1980) 0.80
Localization and role of transcortin-like molecules in the anterior pituitary. Mol Cell Endocrinol (1977) 0.80
[Radioimmunological determination of cyclic 3',5'-AMP. Preparation, purification and checking of tyrosine-succinyl-AMPc and of its iodinated derivatives]. C R Acad Sci Hebd Seances Acad Sci D (1972) 0.79
Adenylate cyclase of rat pituitary gland: stimulation by vasoactive intestinal polypeptide (VIP). FEBS Lett (1979) 0.79
Immunoreactive vasoactive intestinal polypeptide in rat hypophysial portal blood. Endocrinology (1981) 0.79
Absence of nocturnal elevation of plasma prolactin concentrations in Cushing's disease. J Clin Endocrinol Metab (1976) 0.78
Effect of steroids on vasoactive intestinal peptide in discrete brain regions and peripheral tissues. Neuroendocrinology (1980) 0.77
[Effect of vasoactive intestinal peptide (VIP) on prolactin secretion in man]. C R Seances Acad Sci III (1981) 0.77
Separation of antibody-bound and unbound peptide hormones labelled with iodine-131 by talcum powder and precipitated silica. Nature (1966) 3.17
Relationship of plasma insulin levels to the incidence of myocardial infarction and coronary heart disease mortality in a middle-aged population. Diabetologia (1980) 1.74
Impairment of insulin binding to the fat cell plasma membrane in the obese hyperglycemic mouse. FEBS Lett (1972) 1.71
Diabetogenic effect of streptozotocin in the rat during the perinatal period. Diabetes (1974) 1.27
Vasoactive intestinal peptide: a potent stimulator of adenosine 3':5'-cyclic monophosphate accumulation in gut carcinoma cell lines in culture. Proc Natl Acad Sci U S A (1978) 1.21
[The effects of perfusion and amino acid ingestion in glucagonenemia]. Journ Annu Diabetol Hotel Dieu (1967) 1.11
Porcine peptide having N-terminal histidine and C-terminal isoleucine amide (PHI): vasoactive intestinal peptide (VIP) and secretin-like effects in different tissues from the rat. FEBS Lett (1980) 1.11
Autoradiographic localization of glucocorticosteroid and progesterone binding sites in the human post-mortem brain. J Steroid Biochem (1986) 1.08
The relationship of blood pressure with glucose, insulin, heart rate, free fatty acids and plasma cortisol levels according to degree of obesity in middle-aged men. J Hypertens (1996) 1.05
Interactions of glucagon, gut glucagon, vasoactive intestinal polypeptide and secretin with liver and fat cell plasma membranes: binding to specific sites and stimulation of adenylate cyclase. Endocrinology (1974) 1.03
Chicken insulin: radioimmunological characterization and enhanced activity in rat fat cells and liver plasma membranes. Endocrinology (1974) 1.01
Demonstration of specific receptors for EGF--urogastrone in isolated rat intestinal epithelial cells. FEBS Lett (1980) 1.01
High plasma nonesterified fatty acids are predictive of cancer mortality but not of coronary heart disease mortality: results from the Paris Prospective Study. Am J Epidemiol (2001) 0.99
Cyclic AMP production in isolated colonic epithelial crypts: a highly sensitive model for the evaluation of vasoactive intestinal peptide action in human intestine. Eur J Clin Invest (1980) 0.99
Expression of glucagon-like peptide 1 receptor in a murine C cell line: regulation of calcitonin gene by glucagon-like peptide 1. FEBS Lett (1996) 0.98
Evidence for the presence of insulin binding sites in isolated rat intestinal epithelial cells. Diabetologia (1980) 0.97
Chemical diabetes in the adult rat as the spontaneous evolution of neonatal diabetes. Diabetologia (1979) 0.95
Glucagon antibodies. Lancet (1965) 0.95
Histamine and VIP interactions with receptor-cyclic AMP systems in the human gastric cancer cell line HGT-1. Life Sci (1983) 0.92
Interaction of vasoactive intestinal peptide with isolated intestinal epithelial cells from rat. 1. Characterization, quantitative aspects and structural requirements of binding sites. Eur J Biochem (1979) 0.92
Two populations of neurotensin binding sites in murine brain: discrimination by the antihistamine levocabastine reveals markedly different radioautographic distribution. Eur J Pharmacol (1987) 0.92
Vasoactive intestinal peptide (VIP): variation of the jejuno-ileal content in the developing rat as measured by radioreceptorassay. Acta Endocrinol (Copenh) (1977) 0.91
Transfection of fetal rat intestinal epithelial cells by viral oncogenes: establishment and characterization of the E1A-immortalized SLC-11 cell line. Proc Natl Acad Sci U S A (1989) 0.91
Vasoactive intestinal peptide (VIP) stimulates prolactin (PRL) release and cAMP production in a rat pituitary cell line (GH3/B6). Additive effects of VIP and TRH on PRL release. FEBS Lett (1979) 0.90
Vasoactive intestinal peptide (VIP): brain distribution, subcellular localization and effect of deafferentation of the hypothalamus in male rats. Brain Res (1979) 0.90
Differential transferrin receptor density in human colorectal cancer: A potential probe for diagnosis and therapy. Int J Oncol (1998) 0.89
Vasoactive intestinal peptide (VIP) control of glycogenolysis in the human colon carcinoma cell line HT-29 in culture. FEBS Lett (1981) 0.89
[Intestinal vasoactive peptide receptors in enterocytes : specific binding and stimulation of cyclic AMP]. C R Acad Sci Hebd Seances Acad Sci D (1977) 0.89
The interaction of glucagon, gastric inhibitory peptide and somatostatin with cyclic AMP production systems present in rat gastric glands. Biochim Biophys Acta (1982) 0.88
Stimulation of prolactin release by vasoactive intestinal peptide (VIP). Eur J Pharmacol (1978) 0.88
Growth hormone as a risk for premature mortality in healthy subjects: data from the Paris prospective study. BMJ (1998) 0.87
Upper-body fat distribution: a hyperinsulinemia-independent predictor of coronary heart disease mortality. The Paris Prospective Study. Arterioscler Thromb (1992) 0.87
Importance of the vasoactive intestinal peptide receptor in the stimulation of cyclic adenosine 3',5'-monophosphate in gallbladder epithelial cells of man. Comparison with the guinea pig. J Clin Invest (1981) 0.86
"Enterolglucagon': a specific effect on gastric glands isolated from the rat fundus. Evidence for an "oxyntomodulin' action. Biosci Rep (1981) 0.86
Characterization of specific binding sites for vasoactive intestinal peptide in rat intestinal epithelial cell membranes. Biochim Biophys Acta (1980) 0.86
Beta-adrenergic regulation of cyclic adenosine 3',5' monophosphate accumulation in human gastric epithelial glands. Inhibitory effect of somatostatin. Eur J Clin Invest (1984) 0.86
Isolation of glucagon-37 (bioactive enteroglucagon/oxyntomodulin) from porcine jejuno-ileum. Characterization of the peptide. FEBS Lett (1982) 0.86
Vasoactive intestinal peptide control of cyclic adenosine 3':5'-monophosphate levels in seven human colorectal adenocarcinoma cell lines in culture. Cancer Res (1980) 0.86
Experimental chemical diabetes and pregnancy in the rat. Evolution of glucose tolerance and insulin response. Diabetes (1982) 0.86
Isolation of glucagon-37 (bioactive enteroglucagon/oxyntomodulin) from porcine jejuno-ileum. Isolation of the peptide. FEBS Lett (1982) 0.85
A new neuroregulator: the vasoactive intestinal peptide or VIP. Mol Cell Endocrinol (1982) 0.85
Regulation by vasoactive intestinal peptide, histamine, somatostatin-14 and -28 of cyclic adenosine monophosphate levels in gastric glands isolated from the guinea pig fundus or antrum. Endocrinology (1983) 0.85
Hormonal control of phenylalanine hydroxylase activity in isolated rat hepatocytes. Biochem Biophys Res Commun (1980) 0.85
Body mass, blood pressure, glucose, and lipids. Does plasma insulin explain their relationships? Arteriosclerosis (1987) 0.84
The receptors of the VIP family peptides (VIP, secretin, GRF, PHI, PHM, GIP, glucagon and oxyntomodulin). Specificities and identity. Peptides (1986) 0.84
Gonadotrophin release by gonadotrophs incubated with gonadotrophin-releasing hormone is independent of intracellular cAMP accumulation. Acta Endocrinol (Copenh) (1981) 0.84
Postmaturity in the rat: impairment of insulin, glucagon, and glycogen stores. Diabetologia (1976) 0.84
Stimulation of in vitro prolactin release by vasoactive intestinal peptide. Neuroendocrinology (1980) 0.84
Characterization and repartition of epidermal growth factor-urogastrone receptors in gastric glands isolated from young and adult guinea pigs. Biochim Biophys Acta (1984) 0.84
Vasoactive intestinal peptide inhibits release of somatostatin from hypothalamus in vitro. Eur J Pharmacol (1979) 0.83
Nutritionally induced variations in insulinaemia, blood ketone bodies and plasma and liver triglycerides in genetically obese rats. Diabete Metab (1977) 0.83
Characterization of a vasoactive intestinal peptide-sensitive adenylate cyclase in rat intestinal epithelial cell membranes. Biochim Biophys Acta (1978) 0.83
Bioactive enteroglucagon (oxyntomodulin): present knowledge on its chemical structure and its biological activities. Peptides (1981) 0.83
Vasoactive intestinal peptide receptor activity and specificity during enterocyte-like differentiation and retrodifferentiation of the human colonic cancerous subclone HT29-18. FEBS Lett (1985) 0.83
The interaction of secretin with pancreatic membranes. Biochim Biophys Acta (1976) 0.83
Stimulation by dopamine of luteinizing hormone-releasing hormone (LHRH) release from the mediobasal hypothalamus in male rats. Endocrinology (1977) 0.82
[Study of 8 cases of primary hemochromatosis, including in particular the plasma radio-immunologic determination of somatotropic and follicle-stimulating hormones and glucagon]. Pathol Biol (1968) 0.82
Characterization and autoradiographic distribution of vasoactive intestinal peptide binding sites in the rat central nervous system. Brain Res (1986) 0.82
Metabolism of genetically obese rates on normal or high-fat diet. Diabetologia (1974) 0.82
Interaction of amino acids and cyclic AMP on the release of insulin and glucagon by newborn rat pancreas. Endocrinology (1975) 0.81
[Receptors for vasoactic intestinal peptide (VIP) in human colonic adenocarcinoma membranes: specific binding and stimulation of adenylate cyclase]. C R Acad Sci Hebd Seances Acad Sci D (1978) 0.81
Relationship between ACTH release and corticosterone binding by the receptor sites of the adenohypophysis and dorsal hippocampus following infusion of corticosterone at a constant rate in the adrenalectomized rat. Endocrinology (1975) 0.81
Secretin receptor activity in rat gastric glands. Binding studies, cAMP generation and pharmacology. Peptides (1986) 0.81
Glucocorticoid binding sites in human temporal cortex. Brain Res (1988) 0.81
Vasoactive intestinal peptide receptor regulation and reversible desensitization in human colonic carcinoma cells in culture. Cancer Res (1986) 0.81
Effect of vasoactive intestinal peptide (VIP) on the release of adenohypophyseal hormones from purified cells obtained by unit gravity sedimentation. Inhibition by dexamethasone of vip-induced prolactin release. Neuroendocrinology (1980) 0.81
Dynamics of pancreatic cell growth and differentiation during diabetes reversion in STZ-treated newborn rats. Am J Physiol (1995) 0.81
Effect of feeding and fasting on the early steps of glucagon action in isolated rat liver cells. Endocrinology (1976) 0.81
Regulation by vasoactive intestinal peptide of cyclic AMP accumulation in gastric epithelial glands. A characteristic of human stomach. FEBS Lett (1980) 0.81
Characterization of vasoactive intestinal peptide receptors in human colonic epithelial cells. J Clin Endocrinol Metab (1981) 0.81
Growth hormone and insulin binding to isolated hepatocytes in the genetically dwarf mouse. Biochim Biophys Acta (1980) 0.81
Ontogenic development of vasoactive intestinal peptide receptors in rat intestinal cells and liver. Endocrinology (1987) 0.80
Histamine interaction on surface recognition sites of H2-type in parietal and non-parietal cells isolated from the guinea pig stomach. FEBS Lett (1982) 0.80
Selective inhibition by somatostatin of cyclic AMP production in rat gastric glands: demonstration of a direct effect on the parietal cell function. FEBS Lett (1980) 0.80
Biosynthesis of proinsulin and insulin in newborn rat pancreas. Interaction of glucose, cyclic AMP, somatostatin, and sulfonylureas on the (3H) leucine incorporation into immunoreactive insulin. J Clin Invest (1976) 0.80
Vasoactive intestinal peptide (VIP): tissue distribution in the rat as measured by radioimmunoassay and by radioreceptorassay. Acta Endocrinol (Copenh) (1978) 0.80
Portal insulin and glucagon in rats fed proteins as a meal: immediate variations and circadian modulations. J Nutr (1980) 0.80
Development of the beta cells. Mt Sinai J Med (1992) 0.80
Cell-specific localization of G protein alpha-subunits in the islets of Langerhans. J Endocrinol (1999) 0.80
Pharmacology and molecular identification of secretin receptors in rat gastric glands. Life Sci (1988) 0.80
Coexpression of alpha and gamma enolase genes in neurons of adult rat brain. J Neurosci Res (1994) 0.80
[Radioimmunological determination of cyclic 3',5'-AMP. Preparation, purification and checking of tyrosine-succinyl-AMPc and of its iodinated derivatives]. C R Acad Sci Hebd Seances Acad Sci D (1972) 0.79
Secretin binding sites coupled with adenylate cyclase in rat fundic membranes. Peptides (1981) 0.79
Gastric inhibitory peptide (GIP), pancreatic glucagon and vasoactive intestinal peptide (VIP) are cAMP-inducing hormones in the human gastric cancer cell line HGT-1. Homologous desensitization of VIP receptor activity. Biochem Biophys Res Commun (1984) 0.79
Characterization of binding sites for VIP-related peptides and activation of adenylate cyclase in developing pancreas. Am J Physiol (1991) 0.79
Stimulatory transducing systems in pancreatic islet cells. Ann N Y Acad Sci (1998) 0.79
Tissue distribution of 131I radiolabeled transferrin in the athymic nude mouse: localization of a human colon adenocarcinoma HT-29 xenograft. Int J Rad Appl Instrum B (1990) 0.79
Transfer of the hormone receptor for vaso-intestinal peptide to an adenylate cyclase system in another cell. FEBS Lett (1979) 0.79
Rapid inhibition by somatostatin of vasoactive intestinal peptide-induced prolactin secretion by rat pituitary cells. Relationship to cyclic AMP accumulation. FEBS Lett (1982) 0.79
Structural requirements for glucagon receptor binding and activation of adenylate cyclase in liver. Study of chemically modified forms of the hormone, including N alpha-trinitrophenyl glucagon, an antagonist. J Biol Chem (1981) 0.79
Autoradiographic localization of glucocorticosteroid binding sites in rat brain after in vivo injection of [3H]RU 28362. Neurosci Lett (1988) 0.79
[Cyclic AMP, mediator of glucagon secretion due to amino acids]. C R Acad Sci Hebd Seances Acad Sci D (1973) 0.79
Characterization and autoradiographic distribution of neurotensin binding sites in the human brain. Brain Res (1985) 0.79
Glucose intolerance in uraemia. II. Plasma growth hormone and glucagon values. Diabetologia (1969) 0.78
Insulin and glucagon-receptor interactions in the genetically obese Zucker rat: studies of hormone binding and glucagon-stimulated cyclic AMP levels in isolated hepatocytes. Endocrinology (1977) 0.78
Ultrastructural evidence for endogenous vasoactive intestinal peptide-like immunoreactivity in the pituitary gland. Neuroendocrinology (1982) 0.78